

HTANGEL

Keeping you up-to-date on
HTA decisions

Issue 35: March 2026

Cancer drugs drive March wins, while Alzheimer's and rare-disease therapies stumble

This newsletter summarises final decisions from NICE, SMC, HAS & IQWiG from published reports in March 2026.

| Good news

Durvalumab, approved for muscle-invasive bladder cancer in England and for resectable gastric or gastroesophageal junction adenocarcinoma in France; Trastuzumab deruxtecan, approved in Germany for advanced gastric or gastroesophageal junction cancer; and Dupilumab, approved in England for uncontrolled COPD with raised blood eosinophils.

| Bad news

Donanemab, not approved in France for Alzheimer's disease; Pembrolizumab, not approved in Scotland for first-line unresectable non-epithelioid malignant pleural mesothelioma; and Isatuximab, not approved in Scotland for induction treatment of newly diagnosed multiple myeloma.

Approvals

11

Non-approvals

14

HTANGEL

Issue 35: March 2026

Pharmacological Technologies



Scotland
SMC2844

Cancer
Astrocytoma,
Oligodendroglioma
VORASIDENIB

✓ Approved



Scotland
SMC2899

Cancer
Biliary tract cancer
SELADELPAR

✗ Not
approved



England
NICE TA1138

Cancer
Bladder cancer
DURVALUMAB

✓! Approved
with special
conditions



Scotland
SMC2916

Cancer
Breast cancer
SACITUZUMAB
GOVITECAN

✗ Not
approved



England
NICE TA1139

Cancer
Follicular lymphoma
EPCORITAMAB

✓! Approved
with special
conditions



France
HAS AP563

Cancer
Gastric cancer,
Gastroesophageal
junction cancer
DURVALUMAB

✓ Approved



Germany
IQWiG A25-128

Cancer
Gastroesophageal
junction cancer,
Stomach cancer
TRASTUZUMAB DERUXTECAN

✓ Approved



Germany
IQWiG A26-10

Cancer
Gastroesophageal
junction cancer,
Stomach cancer
TRASTUZUMAB DERUXTECAN

✓ Approved

HTANGEL

Issue 35: March 2026

Pharmacological Technologies



Germany
IQWiG A25-153

Cancer
Lymphoma
LISOCABTAGEN
MARALEUCEL



Scotland
SMC2915

Cancer
Mesothelioma
PEMBROLIZUMAB



Scotland
SMC2914

Cancer
Multiple myeloma
ISATUXIMAB



England
NICE TA1141

Cancer
Urothelial cancer
NIVOLUMAB



Germany
IQWiG A25-114

Cardiovascular
Granulomatosis,
Polyangiitis
AVACOPAN




England
NICE TA1143

Endocrine
Vasomotor symptoms,
Menopause
FEZOLINETANT




England
NICE HST35

Genetic & Metabolic
Arginase-1
deficiency
PEGZILARGINASE



Scotland
SMC2800

Genetic & Metabolic
Cystic fibrosis
VANZACAFITOR/
TEZACAFITOR/
DEUTIVACAFITOR



HTANGEL

Issue 35: March 2026

Pharmacological Technologies



Germany
IQWiG A25-158

Infection
COVID-19
NIRMATRELVIR/
RITONAVIR

Not
approved



Germany
IQWiG A25-157

Renal
Glomerulopathy
IPTACOPAN

Not
approved



France
HAS AP561

Neurology
Alzheimer's disease
DONANEMAB

Not
approved



England
NICE TA1142

Respiratory
Chronic obstructive
pulmonary disease
DUPILUMAB

Approved
with special
conditions



Scotland
SMC2845

Neurology
Friedreich's ataxia
OMAVELOXOLONE

Not
approved



France
HAS AP544

Respiratory
Idiopathic pulmonary
fibrosis
NERANDOMILAST

Not
approved



Scotland
SMC2830

Neurology
Myasthenia gravis
ZILUCOPLAN

Not
approved



France
HAS AP543

Respiratory
Progressive
pulmonary fibrosis
NERANDOMILAST

Not
approved



Pharmacological Technologies



England
NICE TA1140

Skin
Vitiligo
RUXOLITINIB




HTANGEL

Issue 35: March 2026

Further Information

HTAngel is designed to help keep you up to date with the latest HTA decisions from NICE, SMC, HAS & IQWiG.

Below is a breakdown of the tiles in the newsletter.



At Crystallise we aim to provide an innovative approach to processing information, using software tools to automate processes that are slower and less accurate when done by humans. Our approach provides clients with greater transparency and scope than they could find for the same budget elsewhere. We work with a network of experts and organisations that help us support clients efficiently and effectively, and are proud of our flexible and ingenious way of solving their problems.

For further information about HTAngel contact
newsletter@crystallise.com

To speak to us about our services contact
contact@crystallise.com

